Industry Wire 217

October 9, 2024 Jake Fishman 0 min read
  1. GLP-1s drive 2% drop in U.S obesity rate.
  2. NYT highlights ChatGPT’s bedside manner advantage.
  3. CVS explores strategic alternatives.
  4. CMS releases Medicare Advantage preliminary 2025 scores.
  5. U.S. News & World Report names Best Children’s Hospitals.
  6. AHA urges Biden to declare IV shortage ‘national emergency.’
  7. Many hospitals not prepared for pediatric ED patients.
  8. Harris proposal: Medicare will cover home care visits.
  9. Florida hospitals evacuate for Milton.
  10. NYT details human placentas’ wound healing potential.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Pharmaceuticals July 12, 2026

CARDIO-TTRansform and The Future of ATTR-CM Drugs July 12, 2026

The ATTR-CM drug race almost got another contender, but AstraZeneca and Ionis' Wainua unexpected Phase 3 trial failure might have actually simplified the field.

polypill

Heart Failure July 9, 2026

POLY-HF and the Possibility of HF Polypills July 9, 2026

Guideline-directed heart failure therapy works, but the biggest hurdle is getting patients to actually take it and fresh results in Nature from the POLY-HF trial suggest a polypill approach could be the answer.

Heart Failure July 2, 2026

Uncertainty Lingers on VNS for HF After Shortened Study July 2, 2026

Freshly published data from LivaNova’s pivotal ANTHEM-HFrEF trial hinted that vagal nerve stimulation might help patients with HFrEF, but the company's early termination decision left some questions unanswered.